Reuters logo
BRIEF-Astellas and Seattle Genetics initiate trial of enfortumab vedotin for ureter cancer patients
October 10, 2017 / 12:44 PM / in 2 months

BRIEF-Astellas and Seattle Genetics initiate trial of enfortumab vedotin for ureter cancer patients

Oct 10 (Reuters) - Astellas Pharma Inc:

* Astellas and Seattle Genetics initiate pivotal trial of Enfortumab Vedotin for patients with locally advanced or metastatic urothelial cancer

* Seattle Genetics - ‍companies also plan to initiate a combination trial of Enfortumab Vedotin with CPI therapy in late 2017​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below